Participation of Pharmacist in the Analysis and Handle of Hypoglycemia Induced by Octreotid
DANG Zi-long1,HE Qiu-yi2,WU Xin-an1*
1. Department of Pharmacy, 1st Hospital of Lanzhou University, Lanzhou 730000, China; 2. Pharmacy Department,The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China
Abstract��OBJECTIVE To share the process of analysis and intervene the adverse drug reaction (ADR) caused by octreotide, and to provide reference for the work mode of clinical pharmacist.METHODS One case of hypoglycemia possibly caused by octreotide was discovered. The clinical pharmacist recommend the doctor to replace octreotide as somatostatin after a review of the relevant information and literatures. Then the clinical pharmacist investigated awareness of hypoglycemia ADR of octreotide among the ICU doctors, and introduced the ADR of octreotide and the difference between octreotide and somatostatin among them.RESULTS After the intervention, the hypoglycemia was corrected and the patient was cured and clinical pharmacists�� working mode was identified.CONCLUSION Clinically, pharmacists should not only have good professional knowledge, but also master the ways and means of communication, in addition to assisting doctors monitoring of adverse drug reactions, also need to continue to explore the work mode.
������,������,���°�. �ٴ�ҩʦ��1��ʹ�ð�������ɵ�Ѫ�ǵIJ����ķ�����Ԥ[J]. �й�ҩѧ��־, 2017, 52(12): 1093-1096.
DANG Zi-long,HE Qiu-yi,WU Xin-an. Participation of Pharmacist in the Analysis and Handle of Hypoglycemia Induced by Octreotid. Chinese Pharmaceutical Journal, 2017, 52(12): 1093-1096.
ZHU X Y, PEI D S. Clinical application of octreotide[J]. Tianjin Pharm(���ҩѧ),2007,19(3):59-62.
[2]
PENG B G, LIANG L J, HU W J, et al. Clinical study of somatostatin on intestinal obstruction[J]. Chin J Gastrointest Surg (�л�θ�������־), 2004, 7(6):474-476.
[3]
HUANG H D, LU C X, REN J L. Clinical application of somatostatin[J]. Chin Pharm J (�й�ҩѧ��־), 1998, 33(9):563-565.
[4]
TRUVEN HEALTH ANALYTICS. Product information of octreotide acetate [DB/OL]. Philadelphia: Micromedexsolutions, 2007(2014) [2017-05-31]. http://www.micromedexsolutions. com/micromedex2/librarian/PFDefaultActionId/evidenc-expert. DoIntegratedSearch#close.
[5]
LI B, GAO B, LI R, et al. Cousal determination of the adverse events and adverse drug reactions in drug clinical trials[J]. Chin J New Drug(�й���ҩ��־),2014,23(12):1465-1470.
[6]
YE M M. Nursing care of a case of hypoglycemia caused by octreotide[J]. J Nursing Rehabilitation (�����뿵��), 2010, 9(10):915-916.
[7]
SCHMID H A, BRUEGGEN J. Effects of somatostatin analogs on glucose homeostasis in rats [J]. J Endocrinol, 2012, 212(1):49-60.
[8]
SCHMID H A, SCHOEFFTER P. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. [J]. Neuroendocrinology, 2004, 80(suppl 1):47-50.
[9]
SUN Y Z,WANG C F,CUI S W. The role of glucagon in the development of type 2 diabetes mellitus[J]. Shanxi Med J (ɽ��ҽҩ��־), 2008, 37(12):1119-1121.
[10]
HARRIS A G. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects[J]. Gut, 1993, 35(suppl 3):1-4.
[11]
LIU K Z, WANG W Z. Growth hormone and diabetes mellitus[J]. J Hebei Tradit Chin Med Pharmacol(�ӱ���ҽҩѧ��), 1996, 8(1):41-43.
[12]
MOIIER N,BAGGER J P,SCHMITZ O,et al. Somatostatin enhances insulin-stimulated glucose uptake in the perfused human forearm[J]. J Clin Endocrinol Metab,1995,80(6):1789-1793.
2017, Vol. 52 
